Ex vivo susceptibility to antimalarial drugs and polymorphisms in drug resistance genes of African *Plasmodium falciparum*, 2016-2023: a genotype-phenotype association study

Jason Rosado[1]*¥, Abebe A. Fola[2,3]¥, Sandrine Cojean[4,5,6]¥, Véronique Sarrasin[4]¥, Romain Coppée[7], Rizwana Zaffaroulah[4], Azza Bouzayene[4], Liliane Cicéron[4], Céline Maréchal[4], Geoffrey Thaboulet[4], Camille Moissant[4], Léa Wallus[4], Ludivine Houzé[4], Nicolas Imbert[4], Rebecca Crudale[2,3], Lise Musset[8], Marc Thellier[9], Bruno Pradines[10,11,12,13], Jérôme Clain[1]*¶, Jeffrey A. Bailey[2,3]¶, Sandrine Houzé[1,4]¶, Investigation Study Group[ψ]

¥: The first authors contributed equally to this work.
¶: Co-senior authors contributed equally to this work.

Authors and affiliations

[1] Université Paris Cité, IRD, MERIT, F-75006 Paris, France
[2] Department of Pathology and Laboratory Medicine, Brown University, RI, USA, 02906
[3] Center for Computational Molecular Biology, Brown University, RI, USA, 02906
[4] Centre National de Référence du Paludisme, Assistance Publique-Hôpitaux de Paris, Hôpital Bichat-Claude-Bernard, Paris, France
[5] Université Paris-Saclay, Faculté de Pharmacie, Orsay, France
[6] UMR BIPAR, Anses, Laboratoire de Santé Animale, INRAE, Ecole Nationale Vétérinaire d'Alfort, Maisons-Alfort, France
[7] Université de Rouen Normandie, Laboratoire de Parasitologie-Mycologie, UR 7510 ESCAPE, Rouen, France
[8] Laboratoire de Parasitologie, World Health Organization Collaborating Center for Surveillance of Antimalarial Drug Resistance, Centre Nationale de Référence du Paludisme, Institut Pasteur de la Guyane, Cayenne, French Guiana
[9] Centre National de Référence du Paludisme, Sorbonne Université, Assistance Publique des Hôpitaux de Paris, Laboratoire de Mycologie et Parasitologie, Hôpital de la Pitié-Salpêtrière, Paris, France
[10] Unité Parasitologie et Entomologie, Département des Maladies Infectieuses, Institut de Recherche Biomédicale des Armées, Marseille, France
[11] Aix Marseille Université, SSA, AP-HM, RITMES, Marseille, France
[12] Centre National de Référence du Paludisme, Marseille, France
[13] IHU-Méditerranée Infection, Marseille, France

*: Corresponding Authors: JR: jjrosados@gmail.com; JC: jerome.clain@u-paris.fr
[ψ]: The members of the study group are listed in acknowledgements.

Keywords: Antimalarial drug resistance, *ex-vivo* susceptibility, IC50 assay, genotype

Abstract

Background: Given the altered responses to both artemisinins and lumefantrine in Eastern Africa, monitoring antimalarial drug resistance in all African countries is paramount.

Methods: We measured the susceptibility to six antimalarials using *ex vivo* growth inhibition assays (IC_{50}) for a total of 805 *Plasmodium falciparum* isolates obtained from travelers returning to France (2016-2023), mainly from West and Central Africa. Isolates were sequenced using molecular inversion probes (MIPs) targeting fourteen drug resistance genes across the parasite genome.

Findings: *Ex vivo* susceptibility to several drugs has significantly decreased in 2019-2023 versus 2016-2018 parasite samples: lumefantrine (median IC_{50}: 23·0 nM [IQR: 14·4-35·1] in 2019-2023 versus 13·9 nM [8·42-21·7] in 2016-2018, p<0·0001), monodesethylamodiaquine (35·4 [21·2-51·1] versus 20·3 nM [15·4-33·1], p<0·0001), and marginally piperaquine (20·5 [16·5-26·2] versus 18.0 [14·2-22·4] nM, p<0·0001). Only four isolates carried a validated *pfkelch13* mutation. Multiple mutations in *pfcrt* and one in *pfmdr1* (N86Y) were significantly associated with altered susceptibility to multiple drugs. The susceptibility to lumefantrine was altered by *pfcrt* and *pfmdr1* mutations in an additive manner, with the wild-type haplotype (*pfcrt* K76-*pfmdr1* N86) exhibiting the least susceptibility.

Interpretation: Our study on *P. falciparum* isolates from West and Central Africa indicates a low prevalence of molecular markers of artemisinin resistance but a significant decrease in susceptibility to the partner drugs that have been the most widely used since a decade -lumefantrine and amodiaquine. These phenotypic changes likely mark parasite adaptation to sustained drug pressure and call for intensifying the monitoring of antimalarial drug resistance in Africa.

Funding: This work was supported by the French Ministry of Health (grant to the French National Malaria Reference Center) and by the Agence Nationale de la Recherche (ANR-17-CE15-0013-03 to JC). JAB was supported by NIH R01AI139520. JR postdoctoral fellowship was funded by Institut de Recherche pour le Développement.

Research in context

Evidence before this study

Artemisinin-based combination therapies (ACTs) have been introduced since the 2000s as the first-line curative treatment of malaria. ACTs combine an artemisinin derivative, which rapidly reduces parasite load, with another antimalarial drug -known as partner drug- which eliminates the remaining parasites thanks to its longer half-life. This approach reduces the likelihood of parasites developing resistance to both drugs, thereby increasing treatment efficacy and delaying the emergence of resistance. However, resistance to artemisinins and then to some partner drugs was identified in Southeast Asia more than a decade ago and has spread throughout the region. Artemisinin partial resistance is now emerging in the East and Horn of Africa. It manifests as delayed parasite clearance from the bloodstream after treatment, increasing the parasite load in contact with the partner drug only and the likelihood of selecting resistant parasites. It is, therefore, important to monitor antimalarial drug susceptibility and drug resistance mutations in contemporary African isolates, especially in the understudied West and Central African regions, to anticipate the spread of multidrug-resistant parasites.

We searched for articles on antimalarial drug resistance published between January 1, 2000, and July 1, 2024, using the PubMed search terms “antimalarial resistance”, “Africa”, and “*ex vivo*”. Of the 69 published studies, only six encompassing a total of 827 isolates across five West and Central African countries from 2016 to 2022 combined *ex vivo* drug assays with genotyping data. Parasites with an increased rate of *ex vivo* survival to artemisinins were reported in one study from Ghana (7/90 isolates in 2018) and another from The Gambia (4/41 isolates in 2017). Only the Ghanaian study reported mutations in the non-propeller domain of *pfkelch13* gene, whereas the Gambian study reported mutations associated with reduced susceptibility to lumefantrine (7%, 3/41). In Mali, Senegal and Burkina Faso, most isolates were susceptible to commonly used antimalarial drugs (chloroquine, amodiaquine, piperaquine, mefloquine, lumefantrine and dihydroartemisinin) using standard growth inhibition assays. In Ghana, reduced susceptibility to artemisinin, mefloquine and amodiaquine was observed. The relative lack of recent data on parasite susceptibility to antimalarial drugs in recent parasites from West and Central Africa prompted us to conduct this study.

Added value of this study

Ex vivo susceptibility to six antimalarial drugs (dihydroartemisinin, lumefantrine, mefloquine, chloroquine, monodesethylamodiaquine, and piperaquine) and mutations in fourteen drug resistance genes were evaluated in 805 isolates collected between January 2016 and February 2023 from 35 African countries, mainly from West and Central Africa.

Median IC_{50} values were in the low nanomolar range, indicating good potency against *P. falciparum*. However, worrying trends emerged from 2019 onwards, with median IC_{50} values for lumefantrine that increased from 13·9 nM in 2016-18 to 23 nM in 2019-23 and for amodiaquine from 20·3 nM to 35·4 nM.

The high prevalence of resistance alleles in *pfdhfr*, *pfdhps*, *pfmdr1* and *pfcrt* genes underscores the sustained pressure exerted by antimalarial drugs on parasite populations. Notably, although the triple mutant *pfdhfr* N51I-C59R-S108N was highly prevalent, the *dhfr-dhps* quintuple mutant (with extra *pfdhps* A437G-K540E), which is responsible for sulfadoxine-pyrimethamine treatment failure in adults and children, was rare. In addition, the analysis revealed some geographic and temporal variations in mutation prevalence.

The genotype-phenotype association analysis performed in this study elucidates the relationship between genetic variants and *ex vivo* drug susceptibility, providing valuable information for understanding the molecular basis of resistance and informing future treatment strategies. For example, mutations in the *pfcrt* and *pfmdr1* genes, mainly K76T and N86Y, were associated with altered susceptibilities to most drugs. Haplotypic association analysis further indicated that the two genes have cumulative effects on the susceptibility to lumefantrine, with the wild-type haplotype (*pfcrt* K76-*pfmdr1* N86) exhibiting the least susceptibility.

Implication of all the available evidence

While the susceptibility to most antimalarials suggests continued efficacy, the observed decrease in susceptibilities to lumefantrine and amodiaquine in parasites from West and Central Africa from 2019 onwards suggests an ongoing adaptation of parasites, possibly related to the increasing use of ACT treatments in Sub-saharan Africa since a decade. These phenotypic changes over time were accompanied by small changes in the prevalence of resistance alleles in *pfcrt* and *pfmdr1* genes. Additional changes, potentially leading to larger decreases in drug susceptibilities, can be

expected over time. The large-scale analysis presented here provides invaluable, contemporary insights into the current landscape of susceptibility to antimalarial drugs and molecular markers of resistance in *P. falciparum* isolates from West and Central Africa. While the data suggests that ACTs and sulfadoxine-pyrimethamine are likely to be effective in these regions, the phenotypic changes we observed call for intensifying the monitoring of antimalarial drug resistance in Africa.

Introduction

Malaria continues to take a heavy toll on public health in Africa. Antimalarials remain a cornerstone in the fight against malaria, and the evolution of drug resistance poses a significant threat to the efficacy of treatment regimens.[1,2] Monitoring antimalarial drug resistance and treatment efficacy is paramount, as drug selection pressures are ongoing, and no alternatives to current first-line treatments will be available in the coming years.[3,4] Artemisinin-based combination therapies (ACTs) as first-line curative treatments that were introduced in the 2000s. ACTs combine an artemisinin derivative, which rapidly reduces parasite load, with another antimalarial drug -known as partner drug- which eliminates the remaining parasites thanks to its longer half-life.

However, the emergence of artemisinin partial resistance (ART-R) has raised concerns about the long-term efficacy of ACTs for effective malaria treatment.[5,6] After ART-R emerged, treatment failures with dihydroartemisinin (DHA)- piperaquine (PPQ) were reported in Southeast Asia as parasites acquired additional resistance to PPQ.[7,8] ART-R has recently emerged in East Africa and the Horn of Africa,[9–11] creating the potential for selection of parasites resistant to the partner drug(s) and threatening the long-term efficacy of ACTs in Africa.[12,13] Worryingly, decreased susceptibility of *P. falciparum* isolates to the partner drug lumefantrine (LMF) has also been reported in northern Uganda.[14,15] In West and Central Africa, treatment efficacy studies have confirmed the clinical efficacy of ACTs in several settings overall.[16,17] However, few studies have reported *ex vivo* antimalarial drug assays for West and Central African isolates, with little evidence of reduced susceptibility to partner drugs.[18,19] Molecular surveillance has also revealed the sporadic presence of validated ART-R *pfkelch13* mutations in these two regions.[20]

To better understand the current situation in West and Central Africa, we analyzed the *ex vivo* susceptibility to six drugs (DHA, LMF, mefloquine (MFQ), chloroquine (CQ), mono-desethylamodiaquine (MDAQ), and PPQ; assessed by growth inhibition assays) of 805 *P. falciparum* isolates collected between 2016 and 2023 from imported malaria cases in returned travelers to mainly West and Central Africa. The isolates were also sequenced using high-throughput molecular inversion probes (MIPs) targeting 815 overlapping targets across fourteen drug resistance genes to determine the prevalence of drug resistance markers and to estimate genetic correlates of drug susceptibility phenotypes.

Methods

Sample and data collection

The French National Malaria Reference Center (FNMRC) coordinates a nationwide network of hospitals in mainland France to survey imported malaria. Blood samples from civilian or military hospitals participating in the FNRMC network were sent to the FNRMC reference laboratory (Bichat Hospital in Paris) (see Study Group). Inclusion criteria were: diagnosis of *P. falciparum* malaria recorded between January 2016 and February 2023 and confirmed by microscopy and PCR, available DNA sample, information on the country visited, and available IC_{50} data against CQ, MFQ, PPQ, MDAQ, LMF and DHA. A total of 813 isolates fulfilled the inclusion criteria.

Ex vivo assays

CQ, DHA, MDAQ, MFQ, LMF, and PPQ were purchased from Alsachim (Illkirch Graffenstaden, France). The susceptibility of the isolates to the antimalarial drugs was assessed without culture adaptation. 100 µL of parasitized erythrocytes (final parasitaemia of 0.5% and a final hematocrit of 1.5%) were aliquoted into 96-well plates preloaded with a concentration gradient of antimalarial drugs. The plates were incubated for 48 hours in a controlled atmosphere of 85% N_2, 10% O_2, 5% CO_2 at 37°C. Drug susceptibilities were determined as half-maximal inhibitory concentrations (IC_{50}s) using the standard 42-hour [^{3}H]hypoxanthine uptake inhibition assay [21] (**Supplementary methods**). Resistance thresholds for the six compounds were previously reported by Pradines, Kaddouri and others .[22–24]

DNA extraction and MIP sequencing of drug resistance genes

Genomic DNA was extracted from 200 µL whole blood using a MagNA Pure automaton (Roche Diagnostics, USA), eluted in 100 µL, and stored at -20°C. DNA extracts from the included samples were sent to Brown University for MIP sequencing. All samples were then genotyped using molecular inversion probes (MIPs, n=815) targeting known drug resistance SNP mutations in 14 genes across the *P. falciparum* genome, as previously described [12,25] (**Table S1, Appendix 2)**. Sequencing was performed on an Illumina NextSeq 550 instrument (150 bp paired-end reads) at Brown University (RI, USA).

MIP data analysis and estimating drug resistance prevalence

Sequencing data processing and variant calling were performed using MIPtools (v0.19.12.13; https://github.com/bailey-lab/MIPTools). The prevalence for each drug resistance marker was calculated as p = x / n * 100, where p is the prevalence, x is the number of infections with mutant alleles, and n is the number of successfully genotyped infections, as previously described.[12] Mixed genotypes, i.e. a sample with a reference allele and an alternative allele in a given sample, were considered mutant regardless of the within-sample mutant allele frequency. Haplotypes were reconstructed for all samples using the major allele in a given codon (**Supplementary methods**).

Phenotype–genotype association analysis

Isolates with >30% missing genotype data were discarded. We then retained only biallelic non-synonymous SNPs with minor allele frequency (MAF) >0.01 for phenotype-genotype association analysis. Phenotype-genotype association was performed with the SNPassoc R package (v.2.1.0) [26] using the built-in WGassociation function under a dominant model. For each drug, a linear regression model was fitted with continuous IC_{50} values as the outcome and individual SNP genotypes as independent variables. The model was adjusted for the complexity of infection (COI), year, and the visited country of imported cases as covariates.

Ethical aspects

Informed consent was not required because the clinical and biological data were collected from the FNMRC database by the common public health mission of all National Reference Centers in France, in coordination with the Santé Publique France organization for malaria surveillance and care. According to article L1221–1.1 of the Public Health Code in France, the study was considered non-interventional research and only required the patient's non-opposition (according to article L1211–2 of the Public Health Code). All data were anonymized before use. The FNMRC got the authorization to use their databases according to the National Data Protection Commission (CNIL) (number 1223103). Human DNA was not analyzed.

Role of the funding source

The funders of the study had no role in design, data collection, data analysis, data interpretation, or writing of the report.

Results

Geographical origin and year of collection

From January 2016 to February 2023, 1,126 *P. falciparum* isolates from travelers were evaluated for *ex vivo* antimalarial drug susceptibility at the FNMRC laboratory. Of these, 813 isolates were included in this study, corresponding to samples with validated IC_{50} for the following six drugs: DHA, LMF, MFQ, MDAQ, CQ, and PPQ. According to reported travel history, infections originated from thirty-five African countries, but most isolates were from travelers who had visited West (59%, 471/805) and Central (38%, 306/805; **Figure 1A**) African countries. The most visited countries were Côte d'Ivoire (27%, 217/805), Cameroon (21%, 169/805), Mali (9%, 69/805), Guinea (7%, 58/805), and Republic of the Congo (6%, 45/805) (**Figure 1A** and **Table S2**). The number of samples collected per year was higher in 2016 (165/805), 2017 (166/805) and 2018 (167/805) than in 2019 (100/805) and beyond (**Figure 1B**). No differences were seen in the distribution of countries between 2016-2018 and 2019-2023 ($p>0·05$, **Table S3**). Travelers were predominantly male (62%), with a median age of 40 years and a median parasitemia of 1·7% (**Table 1**).

Half-maximal inhibitory concentration (IC_{50}) for six antimalarial compounds

IC_{50} values of *P falciparum* 3D7 laboratory reference strain are indicated in **Table S4**. For the isolates tested in this study, the median IC_{50} estimated with the standard growth inhibition assay was less than 30 nM for all assessed antimalarial compounds, consistent with potent activity. The median IC_{50} values for the six drugs were 1·1 nM [IQR: 0·8-1·7] for DHA, 16·7 nM [9·9-27·4] for LMF, 29·5 nM [19·1-45·5] for MFQ, 23·4 nM [17·1-39·0] for MDAQ, 26·7 nM [18·0-41·2] for CQ, and 18·5 nM [15·1-24·3] for PPQ. Using published resistance thresholds,[22–24] 49% of the isolates were classified as resistant to MFQ (IC_{50} > 30 nM), 10% to CQ (IC_{50} > 100 nM), and 3% to MDAQ (IC_{50} > 80 nM). Less than 1% of isolates had an IC_{50} above the threshold for DHA (10 nM), LMF (150 nM) and PPQ (135 nM) (**Figure S1**).

Remarkably, when compared to samples collected in 2016-2018, a significant decrease in susceptibility was observed in 2019-2023 samples for LMF (median IC_{50}: 13·9 nM [IQR: 8·42-21·7] in 2016-2018 versus 23·0 nM [14·4-35·1] in 2019-2023; $p<0·001$), MDAQ (20·3 nM [15·4-33·1] versus 35·4 nM [21·2-51·1]; $p<0·001$), and modestly for PPQ (18·0 nM [14·2-22·4] versus 20·5 [16·5-26·2]; $p<0·001$) (**Figure 2, Table S5**). In contrast, a modest improvement in

susceptibility was observed in 2019-2023 samples for CQ (27·7 nM [19·0-45·0] versus 25·1 nM [17·3-38·9]; p=0·05), and there was no significant change for MFQ. Altered drug susceptibilities between the two time periods were again detected after data stratification into West and Central African countries, except for DHA, which was significantly altered only in samples from Central Africa, and for CQ (**Table S6**), possibly because of less power for CQ. We note that these temporal changes in drug susceptibility were not significant when using 1-year bins during the 2016-2023 study period (**Table S7**). The frequency of CQ-resistant isolates (IC_{50} > 100 nM) decreased nearly by half in 2019-2023 compared to 2016-2018 (7% in 2019-2023 versus 12% in 2016-2018, p<0·05)(**Table S8**).

There were several significant drug-drug IC_{50} correlations, most of which were positive (**Figure S2**). The largest positive correlations involved the following drug pairs: LMF-MFQ, CQ-MDAQ, DHA-LMF, and DHA-MFQ. The negative correlations were much less intense and involved CQ-LMF and CQ-MFQ.

Prevalence of validated antimalarial resistance mutations

Sequence data generated with MIPs covered 43 exons from 14 genes reported to be associated with drug resistance. 805 out of the 813 included isolates were successfully genotyped. The average number of reads per sample was 120 (range: 48-258) (**Figure S3**). Nearly 60% of the isolates (477/805) had a COI >1. We first examined the prevalence of mutations in five robustly validated drug resistance genes: *pfdhfr* and *pfdhps* (associated with resistance to pyrimethamine and sulfadoxine, respectively), *pfcrt* and *pfmdr1* (associated with multidrug resistance), and *pfkelch13* (associated with ART-R).

More than 85% of isolates carried the *pfdhfr* N51**I**, C59**R**, and S108**N** mutations (**Figure 3A**), which were predominantly found as the **IRN** triple mutant haplotype and marginally as the **I**C**N** and N**RN** double mutants (**Figure S4**), regardless of the country of infection (**Figure S5, Table S9**). We found a low prevalence of the *pfdhps* I431**V** (8.5%)**,** K540**E** (6%), A581**G** (8%) and A613**S** (15%) mutations, and a large prevalence of S436**A** and A437**G** (53% and 78%, respectively). At *pfdhps* codons 436-437-540-581 considered jointly (haplotypes, **Figure S4**), single mutants **A**AKA and S**G**KA were the most common haplotypes (35% and 50% respectively). The quintuple mutant *dhfr+dhps* haplotype **IRN**+A437**G**-K540**E**, which is responsible for SP treatment failure in adults and children, was detected in 3% of samples (19/600).

274 In *pfmdr1,* the prevalence of the N86**Y**, Y184**F,** D1246**Y** mutations were 11%, 71%, and 1%,
275 respectively (**Fig 3A)**, and the prevalence of the NYD, N**F**D and **YF**D haplotypes at codons 86-
276 184-1246 were 38·8%, 54·8% and 5·6%, respectively (**Figure S4**). Other minor haplotypes were
277 found in less than 1% of isolates.

278 The *pfcrt* K76**T** mutation was found in 30% of isolates (**Figure 3A**) and was absent in the Central
279 African Republic (**Figure S5**). Regarding the classical eight *pfcrt* codons 74-75-76-220-271-326-
280 356-371, three main haplotypes were detected (**Figure S4**; per country, see **Table S10** and **Figure**
281 **S6**): the wild-type MNKAQNIR (77%) and the mutants **IETSE**N**TI** (also known as Cam783;
282 15%) and **IETSE**NI**I** (also known as GB4; 6%).

283 Four isolates carried a validated *pfkelch13* mutation in the propeller domain (**Figure 3B**): A675**V**
284 (2/734, from Rwanda in 2019 and Uganda in 2020), Y493**H** (1/705, from Mali in 2016), and I543**T**
285 (1/731, from Côte d'Ivoire in 2018). The two isolates carrying the A675**V** mutation showed a
286 susceptibility to DHA (IC_{50} = 1·78 nM and IC_{50} = 1·67 nM) larger than the upper quartile. The
287 A675**V** isolate from Rwanda also had elevated IC_{50} values for LMF (IC_{50} = 41·57 nM) and MFQ
288 (IC_{50} = 49·12 nM). Two other mutations were detected in the propeller domain: A578**S** (8 isolates)
289 that is known as a polymorphism and E612**D** (1 isolate). Most of the other non-synonymous
290 *pfkelch13* mutations occurred in the N-terminal-coding domain (**Figure 3B, Figure S7**), K189**T**
291 being very frequent (58·4%) and also known as polymorphism.

292 Finally, the prevalence of "background" mutations associated with ART-R in South East Asia [27]
293 was low: *pffd* D193**Y** at 0·27%, *pfmdr2* T484**I** at 0%, *pfpib7* C1484**F** at 0·16%, and *pfpp* V1157**L**
294 at 0% (**Table S11**).

295 We then analysed mutation prevalence over time (**Figure 3C, Figures S8** and **S9,** and **Table S12)**.
296 Remarkably, when compared to samples collected in 2016-2018, a significant decrease in
297 prevalence was observed in 2019-2023 samples for *pfcrt* K76**T** (33% in 2016-2018 versus 25% in
298 2019-2023; p<0·05) and *pfmdr1* N86**Y** (14% versus 5%; p<0·001), and there was a nearly
299 significant decrease for *pfmdr1* Y184**F** (73% versus 66%; p=0·07) (**Figure 3C**). The prevalence
300 of the wild-type haplotype at *pfcrt* 76 and *pfmdr1* 86 (K76-N86) was largely dominant across the
301 whole study period and slightly increased from 73% in 2016-2018 to 79% in 2019-2023 (p=0·05,
302 **Figure 3D, Figure S8B**). Analysis of SNP-SNP correlation in isolates from Côte d'Ivoire and

303 Cameroon indicated that *pfmdr1* N86Y and *pfcrt* K76T were not in linkage disequilibrium with
304 each other (**Figure S10**).

305 Association between SNPs and drug susceptibility

306 Genotype-phenotype association analysis across 362 SNPs and susceptibilities to 6 drugs showed
307 several significant associations (**Figure 4, Tables S12** for the full list of associations, and **S13** and
308 **S14** after correction for multiple testing). Most strikingly, multiple well-known SNPs in *pfcrt* were
309 strongly associated with susceptibilities to multiple drugs (CQ, MDAQ, DHA, LMF) and were
310 borderline significant after multiple testing correction for MFQ and PPQ. Mutant *pfcrt* alleles were
311 associated with decreased susceptibility to CQ ($p = 10^{-38}$–10^{-50} for 7 amino acids) and MDAQ
312 ($p = 10^{-6}$–10^{-8} for 7 amino acids) whereas wild-type *pfcrt* alleles were associated with decreased
313 susceptibility to DHA ($p = 10^{-6}$ for 6 amino acids) and LMF ($p = 10^{-5}$ for 3 amino acids). There
314 was also a strong association between the well-characterised mutation N86**Y** in *pfmdr1* and
315 susceptibility to MFQ ($p = 10^{-6}$), LMF ($p = 10^{-5}$), and DHA (p=0·0003, although non-significant
316 after correction). Finally, the *pfubp1* N1704**K** and K1705**N** mutations were associated with
317 decreased susceptibility to CQ ($p = 2 \cdot 10^{-5}$ and 0·0001 respectively).

318 To control for the major *pfcrt* effect, we added *pfcrt* K76T as a covariate (**Table S13**). All the
319 associations involving another SNP in *pfcrt* (except M74I for CQ) and *pfubp1* N1704K and
320 K1705N were lost, suggesting they were dependent on the *pfcrt* K76T genotype. The associations
321 involving *pfmdr1* (with LMF and MFQ) were maintained and no new associations were detected.
322 A model with *pfmdr1* N86Y as a covariate abolished only the association of *pfubp1* K1705N for
323 CQ (but not the one of N1704K) (**Table S13**). These data indicate that, among the 362 tested SNPs,
324 *pfcrt* and *pfmdr1* SNPs were the major drivers of susceptibility to most tested drugs and could
325 interact in a likely additive manner in the case of LMF.

326 Effect of *pfcrt* and *pfmdr1* haplotypes on IC_{50}s

327 As compared to the wild-type *pfcrt* (MNKAQNIR), mutant haplotypes **IETSE**N**TI** and **IETSE**N**II**
328 (that differ at I356**T** only) were significantly associated with decreased susceptibility to CQ and
329 MDAQ (Kruskal-Wallis test, p-value range: <0·0001-0·0003; **Figure S11**) and improved
330 susceptibility to DHA, LMF and PPQ (Kruskal-Wallis test, p-value range: <0·0001- 0·05).
331 **IETSE**N**TI**, but not **IETSE**N**II,** was associated with improved susceptibility to MFQ (Kruskal-
332 Wallis test, p = 0·0001), suggesting that I356**T** has some role in MFQ transport activity.

333 Isolates carrying the *pfmdr1* NYD wild-type haplotype had decreased susceptibility to DHA, LMF,
334 MFQ and improved susceptibility to PPQ as compared to the mutant **YF**D (Kruskal-Wallis test,
335 p-value range: <0·001 - 0·01; **Figure S11**).

336 Finally, the analysis of *pfcrt* K76T - *pfmdr1* N86Y haplotypes identified three main drug patterns
337 (**Figure 5**). The susceptibility to LMF, MFQ, and also marginally to DHA, improved with the
338 number of *pfcrt-pfmdr1* mutations suggesting these mutations work in additive ways. The most
339 decreased susceptibility to LMF was associated with the wild-type haplotype (*pfcrt* K76-*pfmdr1*
340 N86). The susceptibility to CQ and MDAQ decreased mostly with mutant *pfcrt*, and the addition
341 of mutant *pfmdr1* had a lesser effect. The susceptibility to PPQ was more difficult to interpret with
342 little haplotypic effects.

343 Discussion

344 Whereas there are recent reports of emerging ART-R and decreased susceptibility to LMF in *P.*
345 *falciparum* parasites from East Africa, [28] few recent studies have investigated the resistance status
346 of contemporary West and Central African isolates at a large scale. Here, we report the temporal
347 trends of *ex vivo* susceptibilities to six antimalarials using standard growth inhibition assays and
348 their association with mutations in fourteen drug resistance genes in 805 *P. falciparum* samples
349 collected between 2016 and 2023 in returned travelers to West and Central African countries. We
350 found an overall excellent susceptibility of isolates to the six evaluated antimalarials, but the one
351 to ACT partner drugs LMF and MDAQ decreased in recent years. Concomitantly, the prevalence
352 of wild-type *pfcrt* K76 and *pfmdr1* N86 alleles increased in recent years, consistent with a large
353 selective pressure exerted by the use of LMF and the discontinuation of CQ in these regions.
354 Finally, altered susceptibility to most drugs was strongly associated with *pfcrt* and/or *pfmdr1*
355 genotypes.

356 Regarding molecular ART-R, only four isolates among 805 carried a WHO-validated *pfkelch13*
357 mutation. A675**V** was detected in two travelers returning from East Africa (Rwanda and Uganda),
358 consistent with the spread of this mutation in this region.[10,29] The returned traveler from Uganda
359 showed delayed clearance under artesunate therapy,[30] whereas the A675**V** isolate from Rwanda,
360 had elevated IC_{50} values for LMF (41.57 nM) and MFQ (49.12 nM), consistent with clinical and
361 *ex vivo* data reported by others for Ugandan A675**V** isolates.[11,14,15] Two other validated mutations,

362 Y493**H** and I543**T**, were identified in one isolate from Mali in 2016 and one from Côte d'Ivoire in
363 2018, respectively. These isolates did not have unusual IC_{50}s against any of the drugs tested. As
364 these two mutations were not detected in more recent samples, these seem to be sporadic cases.
365 Altogether, *pfkelch13* ART-R mutations were detected but uncommon in Central and West African
366 isolates during the study period (2016-2023). Contrary to the current situation in East Africa,
367 *pfkelch13*-mediated ART-R is seemingly not emerging during 2016-2023 in West and Central
368 African regions. Continuous monitoring of *pfkelch13* mutations should however be reinforced as
369 they could either emerge locally or be introduced in these regions by intracontinental migration
370 from East Africa.

371 We found a significant reduction in susceptibility of *P. falciparum* to LMF and MDAQ for samples
372 collected in recent years. LMF and MDAQ are the two main partner drugs used in West and Central
373 Africa during the last decade. The use of ACTs may have selected parasites whose response to the
374 partner's drug is altered in these regions. A similar trend was previously reported for LMF in
375 northern Uganda,[14] which possibly predated the emergence of ART-R in this region. [10] The clinical
376 effects of the decreased susceptibilities to LMF and MDAQ observed in our study are unknown,
377 but the spread of ART-R may be facilitated in such phenotypic backgrounds.

378 Remarkably, wild-type *pfcrt* and *pfmdr1* genes were individually associated with decreased
379 susceptibility to LMF, consistent with previous *in vitro* and clinical findings.[31,32,33] Haplotypic
380 association analysis further suggests that the two genes have cumulative effects, with the wild-
381 type haplotype (*pfcrt* K76-*pfmdr1* N86) exhibiting the largest decrease in susceptibility to LMF.
382 The increasing prevalence in recent years of parasites carrying the wild-type allele at either gene
383 or at both could, therefore, explain the LMF data. In contrast the double mutant haplotype (*pfcrt*
384 76T-*pfmdr1* 86Y) exhibited the largest decrease in susceptibility to MDAQ. Taken together, these
385 findings support the rationale for implementing regimens with drug combinations that exert
386 opposing selective pressures.[34] Of note, susceptibility to MDAQ decreased in recent years,
387 whereas the prevalence of the *pfcrt* K76**T** mutation decreased slightly. This is surprising as this
388 mutation is strongly associated with decreased susceptibility to MDAQ in our dataset and other
389 studies. We have no solid explanation for this result, but one possibility could be that other
390 mediators of altered susceptibility to MDAQ exist and that our targeted MIP sequencing and
391 association studies did not capture them.

392 Intriguingly, two novel *pfubp1* mutations, N1704**K** and K1705**N,** were associated with reduced
393 susceptibility to CQ in our data set. The effect of these *pfubp1* mutations seems to depend on the
394 *pfcrt* K76**T** genotype. However, as these two mutations have low prevalence (10.0 and 7.9%,
395 respectively) and likely a modest effect, we have low statistical power to conduct a haplotypic
396 analysis. Several studies reported an association of different *upb1* mutations with altered survival
397 or susceptibility to DHA in mouse malaria or *P. falciparum*,[35,14] and recently to MFQ, LMF and
398 PPQ in the *Plasmodium yoelii* mouse malaria model.[36] However, as the two new mutations are
399 located in an N/K repeat protein region that is not part of the reported active site(s) of the enzyme,
400 gene editing experiments are needed to formally address their role in modulating drug response to
401 CQ.[37]

402 The high prevalence of pyrimethamine resistance mutations in the study period indicates the high
403 level of SP pressure in West and Central Africa. Nevertheless, the low prevalence of *pfdhps* K540E
404 (<10%) and of the SP-resistant quintuple *dhfr-dhps* mutant (3%) is reassuring that SP is still
405 effective for preventive therapies. Indeed, the WHO recommends for countries to withdraw SP for
406 IPTp use when the prevalence of *Pfdhps* K540E>95% and A581G>10% and for IPTi use when
407 the prevalence of *Pfdhps* K540E >50%.[38]

408 This study was not conducted without limitations. First, we have not evaluated *ex vivo* resistance
409 to artemisinin derivatives with the dedicated ring survival assay, the standard measure of in vitro
410 susceptibility to artemisinins. We, however, report very rare ART-R mutations in *pfkelch13,* and
411 at this time, these are the major determinants of ART-R in patients. Second, we have not evaluated
412 copy number variations in *pfmdr1* and *pfplasmepsins 1-2* that are associated with altered
413 susceptibility to MFQ and PPQ, respectively. Third, our geographical coverage of West and
414 Central Africa is biased, with two countries contributing to almost 50% of the total isolate sampling
415 (169 isolates from Cameroon in Central Africa and 217 isolates from Côte d'Ivoire in West Africa).
416 Therefore, trends at the country level could not be robustly drawn. Fourth, our analyses focused
417 on imported malaria cases to France and infections in travelers may differ in several aspects from
418 those in people living in endemic areas. Finally, we used a targeted sequencing approach to
419 genotype isolates and focused on validated and some candidate drug resistance genes. Detecting
420 emerging resistance mutations in novel genes would need a larger genomic coverage.

In conclusion, our study provides much-needed information on molecular and phenotypic resistance in contemporary isolates from West and Central Africa. It shows how current and past control efforts have been affecting malaria parasite populations in those regions and calls for intensifying the monitoring to inform as quickly as possible on future changes regarding antimalarial drug susceptibilities and resistance.

Author contributions

JR, AAF, SC, VS, RCo, JC, JAB, and SH designed the study. SC, VS, RZ, AB, LC, CM, GT, CM, LW, LH, and NI did the ex-vivo IC_{50} assays, and archived data. LM, MT, BP, JC and SH provided administrative and logistical support. JR, AAF, JC, RCr, and JAB analysed and did the genotyping. JR and AAF verified and analysed the data and did the statistical analysis. All authors had full access to all the data. All authors contributed to the writing of the manuscript.

Acknowledgements

We thank the participants who anonymously agreed to participate in a malaria drug resistance surveillance study in France, the staff at the CNR for their support in collecting isolates and executing the drug resistance test, Justine Bailly at MERIT unit, and Alec Leonetti's MIP sequencing support at Brown University. The members of the French National Reference Centre for Imported Malaria Study Group are as follows:Dr A. Aboubacar (CHU Strasbourg), Dr P. Agnamey (CHU Amiens), Dr A. Ahmed (CHU Strasbourg), Dr D. Ajzenberg (CHU Limoges), Dr A. Angoulvant (CHU Bicetre), Dr F. Ariey (CHU Cochin, Paris), Dr B. Aubry (CH Le Mans), Pr F. Banisadr (CHU Reims), Dr S. Belaz (CHU Pontchaillou Rennes), Dr S. Belaz (CHU Pontchaillou, Rennes), Dr G. Belkadi (CHU Saint Antoine, Paris), Dr A. Bellanger (CHU Jean Minjoz,-Besancon), Dr D. Bemba (CHU Jean Verdier, Bondy), Dr F. Benaoudia (CH Troyes), Dr J. Benjamin Murat (CH Roanne), Dr M. Bloch (CHU Louis Mourier, Colombes), Dr F. Botterel (CHU Henri Mondor, Créteil), Dr V. Bouden (CH Saint-Nazaire), Dr M. Bougnoux (CHU Necker Enfants Malades, Paris), Dr C. Brump (CHU Lariboisière, Paris), Dr S. Brun (CHU Avicenne, Bobigny), Dr J. Brunet (CHU Strasbourg), Dr B. Buret (CH Niort), Dr P. Caraux-Paz (CH Villeneuve St Georges), Dr N. Celine (CHU Clermont Ferrand), Dr A. Cherif Touil (CH Niort), Dr S. Clauser (CHU Ambroise Paré, Boulogne Billancourt), Dr E. Collin (CH R Ballanger, Aulnay sous-bois), Dr N. Dahane (CHU Cochin, Paris), Dr C. Damiani (CHU Amiens), Dr E. Dannaoui (CHU HEGP, Paris), Dr C. Dard (CHU Grenoble), Pr M. Darde (CHU Limoges), Dr L. De Gentile (CHU Angers), Dr A. Debourgogne (CHU Nancy), Dr T. Delacour (CH Creil), Dr J. Delarbre (CH Mulhouse), Dr A. Delaval (CH R Ballanger, Aulnay sous-bois), Dr V. Delcey (CHU Lariboisière, Paris), Dr A. Deleplancque (CHU Lille), Dr G. Desoubeaux (CHU Bretonneau, Tours), Dr G. Desoubeaux (CHU Tours), Dr N. Desuremain (CHU Armand Trousseau, Paris), Dr G. Dewulf (CH Valenciennes),Dr R. Durand (CHU Avicenne, Bobigny), Dr M. Durieux (CHU Limoges), Dr

E. Dutoit (CHU Lille), Dr M. Edith (CH Valenciennes), Dr O. Eloy (CH André Mignot, Le Chesnay), Dr M. Evrard Sylvie (CH Villeneuve St Georges), Dr J. Faucher (CHU Limoges), Pr L. Favennec (CHU Ch,Pr A. Faye (CHU Robert Debre, Paris), Dr O. Fenneteau (CHU Robert Debre, Paris), Dr C. Ficko (Hia Begin, Saint-Mandé), Dr E. Frealle (CHU Lille), Dr R. Gabrielle (CH Tourcoing), Pr G. Gargala (CHU Ch, Dr G. Gargala (CHU Rouen), Dr C. Garnaud (CHU Grenoble), Dr N. Godineau (CH Delafontaine, Saint-Denis), Dr J. Gorlicki (CHU Lariboisière, Paris), Dr A. Gravet (CH Mulhouse), Dr N. Guennouni (CHU Bicetre, Le Kremlin Bicêtre), Dr S. Hamane (CHU Saint-Louis, Paris), Dr T. Hanslik (CHU Ambroise Paré, Boulogne Billancourt), Dr A. Huguenin (CHU Reims), Dr F. Jeddi (CHU Nantes), Dr L. Jordan (CHU Lille), Dr L. Landraud (CHU Louis Mourier, Colombes), Dr H. Lapillonne (CHU Armand Trousseau, Paris), Dr S. Larréché (Hia Begin, Saint-Mandé), Dr R. Lavergne (CHU Nantes), Dr Y. Le Govic (CHU Angers), Dr G. Le Moal (CHU Poitiers), Dr E. Lesteven (CHU Lariboisière, Paris), Dr A. Li (CH Creil), Dr C. Lohmann (CH Mulhouse), Dr B. Louise (CHU Dijon), Dr M. Machouart (CHU Nancy), Dr C. Malassigne (CH Le Havre), Dr A. Marteau (CHU Avicenne, Bobigny), Dr D. Maubon (CHU Grenoble), Dr E. Mazars (CH Valenciennes), Pr B. Megarbane (CHU Lariboisière, Paris), Dr A. Mendes-Moreira (CH La Rochelle), Dr S. Mermond (GH La Rochelle), Dr A. Moreno (CHU Saint Antoine, Paris), Dr P. Mornand (CHU Armand Trousseau, Paris), Dr J. Murat (CHU Limoges), Dr R. Nabias (CH Poissy/Saint-Germain-En-Laye), Dr J. Naudin (CHU Robert Debre, Paris), Dr G. Nevez (CHU Brest), Pr G. Nevez (CHU La Cavale Blanche, Brest), Dr C. Nourrisson (CHU Clermont-Ferrand), Dr M. Oussama (CHU Pitié Salpetrière, Paris), Dr N. Parez (CHU Louis Mourier, Colombes), Dr G. Pean-De-Ponfilly (CHU Lariboisière, Paris), Dr J. Peltier (CH Poissy/Saint-Germain-En-Laye), Dr P. Penn (CH Le Mans), Dr A. Perignon (CHU Pitié Salpetrière, Paris), Dr E. Perraud-Cateau (CHU Poitiers), Dr A. Pfaff (CHU Strasbourg), Dr J. Philippe Lemoine (CHU Angers), Dr J. Pilo (Hia Begin, Saint-Mandé), Dr I. Poilane (CHU Jean Verdier, Bondy), Dr D. Poisson (CH Orléans), Dr D. Pons (CHU Clermont Ferrand), Dr L. Pull (CHU Robert Debre, Paris), Dr D. Quinio (CHU Brest), Dr D. Quinio (CHU La Cavale Blanche, Brest), Dr D. Raffenot (CH Chambery), Dr M. Revest (CHU Pontchaillou, Rennes), Dr G. Robert (CHU Grenoble), Dr O. Rogeaux (CH Chambery), Dr M. Sasso (CHU Caremeau Nimes), Dr F. Schmitt (CH Mulhouse), Dr B. Sendid (CHU Lille), Dr Y. Senghor (Groupe Hospitalier Saint Joseph, Paris), Dr M. Silva (CH Jacques Monod, Le Havre), Dr J. Siriez (CHU Robert Debre, Paris), Dr J. Siriez (CHU Robert Debré, Paris), Dr E. Sitterlé (CHU Necker Enfants Malades, Paris), Dr F. Sorge (CHU Necker Enfants Malades, Paris), Dr I. Tantaoui (CHU Pitie-Salpetriere, Paris), Dr D. Toubas (CHU Reims), Dr C. Tournus (CH Saint-Denis), Dr H. Yera (CHU Cochin, Paris), Dr J.Hurst (CH Jacques Monod, Le Havre), Dr C.Leprince (CH R Ballanger, Aulnay sous-bois), Dr P.Patoz (CH Tourcoing), Dr M.Pihet (CHU Angers), Dr P.Poirier (CHU Clermont Ferrand).

Conflict of interest

The authors declare no conflicts of interest.

494 # Data availability

495 All sequencing data are available under accession no. SAMN42141774 to SAMN42142576 at the
496 Sequence Read Archive (SRA), and the associated BioProject ID is PRJNA1129163. De-identified
497 datasets generated during the current study and used to make all figures are available as
498 supplementary files or tables. Software packages and tools useful when working with MIP data
499 are available at https://github.com/bailey-lab/MIPTools and https://github.com/Mrc-
500 ide/mipanalyzer.

501 # References

502 1 Ménard D, Khim N, Beghain J, *et al.* A Worldwide Map of *Plasmodium falciparum* K13-
503 Propeller Polymorphisms. *N Engl J Med* 2016; **374**: 2453–64.

504 2 Rosenthal PJ, Asua V, Conrad MD. Emergence, transmission dynamics and mechanisms
505 of artemisinin partial resistance in malaria parasites in Africa. *Nat Rev Microbiol* 2024;
506 published online Feb 6. DOI:10.1038/s41579-024-01008-2.

507 3 Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the
508 storm? *Lancet Infect Dis* 2019; **19**: e338–51.

509 4 Watson OJ, Gao B, Nguyen TD, *et al.* Pre-existing partner-drug resistance to artemisinin
510 combination therapies facilitates the emergence and spread of artemisinin resistance: a
511 consensus modelling study. *Lancet Microbe* 2022; **3**: e701–10.

512 5 Phyo AP, Nkhoma S, Stepniewska K, *et al.* Emergence of artemisinin-resistant malaria on
513 the western border of Thailand: a longitudinal study. *Lancet* 2012; **379**: 1960–6.

514 6 Noedl H, Se Y, Schaecher K, *et al.* Evidence of artemisinin-resistant malaria in western
515 Cambodia. *N Engl J Med* 2008; **359**: 2619–20.

516 7 Amaratunga C, Lim P, Suon S, *et al.* Dihydroartemisinin-piperaquine resistance in
517 *Plasmodium falciparum* malaria in Cambodia: a multisite prospective cohort study. *Lancet*
518 *Infect Dis* 2016; **16**: 357–65.

519 8 Leang R, Taylor WRJ, Bouth DM, *et al.* Evidence of *Plasmodium falciparum* Malaria
520 Multidrug Resistance to Artemisinin and Piperaquine in Western Cambodia:
521 Dihydroartemisinin-Piperaquine Open-Label Multicenter Clinical Assessment. *Antimicrob*
522 *Agents Chemother* 2015; **59**: 4719–26.

523 9 Uwimana A, Legrand E, Stokes BH, *et al.* Emergence and clonal expansion of in vitro
524 artemisinin-resistant *Plasmodium falciparum* kelch13 R561H mutant parasites in Rwanda.
525 *Nat Med* 2020; **26**: 1602–8.

526 10 Conrad MD, Asua V, Garg S, *et al.* Evolution of partial resistance to artemisinins in malaria
527 parasites in Uganda. *N Engl J Med* 2023; **389**: 722–32.

528 11 Balikagala B, Fukuda N, Ikeda M, *et al.* Evidence of Artemisinin-Resistant Malaria in Africa.
529 *N Engl J Med* 2021; **385**: 1163–71.

530 12 Fola AA, Feleke SM, Mohammed H, *et al. Plasmodium falciparum* resistant to artemisinin
531 and diagnostics have emerged in Ethiopia. *Nat Microbiol* 2023; **8**: 1911–9.

532 13 Mihreteab S, Platon L, Berhane A, *et al.* Increasing Prevalence of Artemisinin-Resistant
533 HRP2-Negative Malaria in Eritrea. *N Engl J Med* 2023; **389**: 1191–202.

534 14 Tumwebaze PK, Conrad MD, Okitwi M, *et al.* Decreased susceptibility of *Plasmodium*
535 *falciparum* to both dihydroartemisinin and lumefantrine in northern Uganda. *Nat Commun*
536 2022; **13**: 1–12.

537 15 van Schalkwyk DA, Pratt S, Nolder D, *et al.* Treatment Failure in a UK Malaria Patient
538 Harboring Genetically Variant *Plasmodium falciparum* From Uganda With Reduced In Vitro
539 Susceptibility to Artemisinin and Lumefantrine. *Clin Infect Dis* 2024; **78**: 445–52.

540 16 Marwa K, Kapesa A, Baraka V, *et al.* Therapeutic efficacy of artemether-lumefantrine,
541 artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of
542 uncomplicated *Plasmodium falciparum* malaria in Sub-Saharan Africa: A systematic review
543 and meta-analysis. *PLoS One* 2022; **17**: e0264339.

544 17 Ishengoma DS, Mandara CI, Bakari C, *et al.* Evidence of artemisinin partial resistance in
545 North-western Tanzania: clinical and drug resistance markers study. bioRxiv. 2024;
546 published online Feb 1. DOI:10.1101/2024.01.31.24301954.

547 18 Mbye H, Mane K, Diop MF, *et al. Plasmodium falciparum* merozoite invasion ligands, linked
548 antimalarial resistance loci and ex vivo responses to antimalarials in The Gambia. *J*
549 *Antimicrob Chemother* 2022; **77**: 2946–55.

550 19 Somé AF, Conrad MD, Kabré Z, *et al.* Ex vivo drug susceptibility and resistance mediating
551 genetic polymorphisms of *Plasmodium falciparum* in Bobo-Dioulasso, Burkina Faso.
552 *Antimicrob Agents Chemother* 2024; **68**: e0153423.

553 20 Ndwiga L, Kimenyi KM, Wamae K, *et al.* A review of the frequencies of *Plasmodium*
554 *falciparum* Kelch 13 artemisinin resistance mutations in Africa. *Int J Parasitol Drugs Drug*
555 *Resist* 2021; **16**: 155–61.

556 21 Kaddouri H, Nakache S, Houzé S, Mentré F, Le Bras J. Assessment of the drug
557 susceptibility of *Plasmodium falciparum* clinical isolates from africa by using a Plasmodium
558 lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for
559 precise measurement of the 50-percent inhibitory concentration. *Antimicrob Agents*
560 *Chemother* 2006; **50**: 3343–9.

561 22 Pascual A, Madamet M, Briolant S, *et al.* Multinormal in vitro distribution of *Plasmodium*
562 *falciparum* susceptibility to piperaquine and pyronaridine. *Malar J* 2015; **14**: 49.

563 23 Kaddouri H, Djimdé A, Dama S, *et al.* Baseline in vitro efficacy of ACT component drugs on
564 *Plasmodium falciparum* clinical isolates from Mali. *Int J Parasitol* 2008; **38**: 791–8.

565 24 Pradines B, Tall A, Rogier C, *et al.* In vitro activities of ferrochloroquine against 55
566 Senegalese isolates of *Plasmodium falciparum* in comparison with those of standard

567 antimalarial drugs. *Trop Med Int Health* 2002; **7**: 265–70.

568 25 Aydemir O, Janko M, Hathaway NJ, *et al.* Drug-Resistance and Population Structure of
569 *Plasmodium falciparum* Across the Democratic Republic of Congo Using High-Throughput
570 Molecular Inversion Probes. *J Infect Dis* 2018; **218**: 946–55.

571 26 González JR, Armengol L, Solé X, *et al.* SNPassoc: an R package to perform whole
572 genome association studies. *Bioinformatics* 2007; **23**: 644–5.

573 27 Miotto O, Amato R, Ashley EA, *et al.* Genetic architecture of artemisinin-resistant
574 *Plasmodium falciparum. Nat Genet* 2015; **47**: 226–34.

575 28 Rosenthal PJ, Asua V, Bailey JA, *et al.* The emergence of artemisinin partial resistance in
576 Africa: how do we respond? *Lancet Infect Dis* 2024; published online March 26.
577 DOI:10.1016/S1473-3099(24)00141-5.

578 29 van Loon W, Oliveira R, Bergmann C, *et al.* In Vitro Confirmation of Artemisinin Resistance
579 in *Plasmodium falciparum* from Patient Isolates, Southern Rwanda, 2019. *Emerg Infect Dis*
580 2022; **28**: 852–5.

581 30 Coppée R, Bailly J, Sarrasin V, *et al.* Circulation of an Artemisinin-Resistant Malaria
582 Lineage in a Traveler Returning from East Africa to France. *Clin Infect Dis* 2022; **75**: 1242–
583 4.

584 31 Dhingra Satish K., Gabryszewski Stanislaw J., Small-Saunders Jennifer L., *et al.* Global
585 Spread of Mutant PfCRT and Its Pleiotropic Impact on *Plasmodium falciparum* Multidrug
586 Resistance and Fitness. *MBio* 2019; **10**: 10.1128/mbio.02731–18.

587 32 Sisowath C, Petersen I, Veiga MI, *et al.* In Vivo Selection of *Plasmodium falciparum*
588 Parasites Carrying the Chloroquine-Susceptible pfcrt K76 Allele after Treatment with
589 Artemether-Lumefantrine in Africa. *J Infect Dis* 2009; **199**: 750–7.

590 33 Windle ST, Lane KD, Gadalla NB, *et al.* Evidence for linkage of pfmdr1, pfcrt, and pfk13
591 polymorphisms to lumefantrine and mefloquine susceptibilities in a *Plasmodium falciparum*
592 cross. *Int J Parasitol Drugs Drug Resist* 2020; **14**: 208–17.

593 34 van der Pluijm RW, Tripura R, Hoglund RM, *et al.* Triple artemisinin-based combination
594 therapies versus artemisinin-based combination therapies for uncomplicated *Plasmodium*
595 *falciparum* malaria: a multicentre, open-label, randomised clinical trial. *Lancet* 2020; **395**:
596 1345–60.

597 35 Borrmann S, Straimer J, Mwai L, *et al.* Genome-wide screen identifies new candidate
598 genes associated with artemisinin susceptibility in *Plasmodium falciparum* in Kenya. *Sci*
599 *Rep* 2013; **3**: 1–10.

600 36 Xu R, Lin L, Jiao Z, *et al.* Deaggregation of mutant Plasmodium yoelii de-ubiquitinase UBP1
601 alters MDR1 localization to confer multidrug resistance. *Nat Commun* 2024; **15**: 1774.

602 37 Singh BK, Zhang C, Wu J, *et al.* A *Plasmodium falciparum* RING Finger E3 Ubiquitin Ligase
603 Modifies the Roles of PfMDR1 and PfCRT in Parasite Drug Responses. *Antimicrob Agents*
604 *Chemother* 2023; **67**: e0082122.

605 38 Okell LC, Griffin JT, Roper C. Mapping sulphadoxine-pyrimethamine-resistant *Plasmodium*

falciparum malaria in infected humans and in parasite populations in Africa. *Sci Rep* 2017; **7**: 7389.

Table 1. Epidemiological characteristics of travelers returning to France and description of isolates from 2016 - 2023

Participant characteristics	**n = 805**
Age, median [IQR]	39.2 [27.1, 51.40]
Sex, n (%)	
Female	306 (38.0%)
Male	499 (62.0%)
Isolates characteristics	
Parasitemia* % (Parasites / 100 RBC), median [IQR]	1.70 [0.81, 3.46]

IQR: Interquartil range; RBC: Red blood cells. * Missing data for two isolates.

640

641

642

643

644

645

646

647

648

649

650

651

652



Figure 1. Geographical origin and collection year of isolates. A) Map of Africa showing the origin of malaria cases imported into France. Colors indicate sample size, and countries with fewer than three isolates are not shown. **B)** Bar plot showing the temporal distribution of imported malaria cases included in this study.



Figure 2. Half-maximal inhibitory concentration (IC_{50}) for six antimalarial drugs. A) Distribution of IC_{50} for the six antimalarial drugs in 2016-18 and 2019-23. Box plots show the median IC_{50} (in nM) and interquartile range. Change in susceptibility over time was tested by Mann-Whitney test. P-values were adjusted using Benjamini-Hochberg correction.



Figure 3. Prevalence of key mutations associated with resistance to different drugs. **A)** Prevalence of key mutations in *pfcrt*, *pfdhfr*, *pfdhps* and *pfmdr1* genes detected in isolates from this study. **B)** Prevalence of mutations in the *pfkelch13* gene. Green bar plots indicate the prevalence of mutations in the N-terminal-coding domain, while orange bar plots indicate the prevalence of mutations in the propeller domain. SNPs marked with an asterisk (*) are validated or candidate SNPs by WHO. **C)** Prevalence of the main key mutations in *pfcrt* and *pfmdr1* over time. **D)** Prevalence of *pfcrt* 76-*pfmdr1* 86 haplotypes over time. Color code for the 4 haplotypes: purple, wild-type K76-N86; green, single mutant K76-86**Y**; blue, single mutant 76**T**-N86; red, double mutant 76**T**-86**Y**. P-values were calculated by Fisher's exact test.



Figure 4. Manhattan plot showing the significance of SNPs associated with six antimalarial drugs. Each dot represents 1 of 362 SNPs with MAF>0·01 colored by chromosome. The x-axis represents the chromosomal location of the SNPs, and the y-axis represents the -log10 of the P-value obtained from the linear regression model analysis. The blue line represents the nominal P-value ($P \leq 0{\cdot}05$), and the red line represents the P-value after Bonferroni correction ($P \leq 1x10^{-4}$). The full list of SNPs associated with IC50 is shown in **Table S13**.



Figure 5. Effect of *pfcrt* 76-*pfmdr1* 86 haplotypes on IC_{50} for six drugs. A) IC_{50} for mefloquine (MFQ), lumefantrine (LMF) and dihydroartemisinin (DHA) disaggregated by *pfcrt-pfmdr1* haplotypes. B) IC_{50} for chloroquine (CQ), monodesethylamodiaquine (MDAQ) and piperaquine (PPQ) disaggregated by *pfcrt-pfmdr1* haplotypes. Haplotypes were built with *pfcrt* K76T and *pfmdr1* N86Y using the major allele per position. n: number of isolates carrying the haplotype. Differences in the IC_{50} of wild-type (WT|WT, crt-K76|mdr1-N86) versus single mutants (Mut|WT, crt-76T|mdr1-N86), (WT|Mut, crt-K76|mdr1-86Y), and double mutant (Mut|Mut, crt-76T|mdr1-86Y) were calculated with a Pairwise Wilcoxon tests with Benjamini-Hochberg correction. *: p<0·05; **: p<0·001.